Zyphar's Pharmaceutics Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Zyphar's Pharmaceutics Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $26.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zyphar's Pharmaceutics Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $26.1K Trade | TransData Nexus

Zyphar's Pharmaceutics Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $26.1K Total Trade · DGFT Verified

Zyphar's Pharmaceutics Private Limited is an Indian pharmaceutical exporter with a total trade value of $26.1K across 3 products in 2 therapeutic categories. Based on 31 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Procarbazine ($13.4K), Adalimumab ($9.4K), Lomustine ($3.3K).

Zyphar's Pharmaceutics Private Limited — Export Portfolio & Destination Treemap

Zyphar's Pharmaceutics Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Zyphar's Pharmaceutics Private Limited? — Company Overview & Market Position

Zyphar's Pharmaceutics Private Limited, incorporated on February 17, 2006, is a privately held Indian pharmaceutical company headquartered in Pune, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24231PN2006PTC022042. Its authorized and paid-up capital stands at ₹4.95 crore (approximately $660,000 USD). The registered office is located at Office No. 102 & 103, Park Plaza, First Floor, Opp Kamala Nehru Park, Erandwane, Pune, Maharashtra 411004, India.

Zyphar's Pharmaceutics specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in two therapeutic categories: Advanced Oncology (64.1%) and Biologics & Immunotherapy (35.9%). The top three exported products are Procarbazine ($13K, Rank #5, 3.5% market share), Adalimumab ($9K, Rank #8, 0.8% market share), and Lomustine ($3K, Rank #7, 3.2% market share). The total export value amounts to $26K USD across 31 shipments, indicating a focused export strategy.

What Does Zyphar's Pharmaceutics Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Procarbazine$13.4K

Product Portfolio — Top 3 by Export Value

Zyphar's Pharmaceutics Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Procarbazine	Advanced Oncology	$13.4K	12	3.5%	5
2	Adalimumab	Biologics & Immunotherapy	$9.4K	5	0.8%	8
3	Lomustine	Advanced Oncology	$3.3K	14	3.2%	7

Zyphar's Pharmaceutics Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $26.1K. The top category is Advanced Oncology (64.1% of portfolio), followed by Biologics & Immunotherapy (35.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Zyphar's Pharmaceutics Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Zyphar's Pharmaceutics operates manufacturing facilities in Pune, Maharashtra. While specific details regarding plant capacities and specializations are not publicly disclosed, the company's focus on oncology and biologics suggests that its facilities are equipped to handle the production of complex formulations in these therapeutic areas.

3Key Leadership

The leadership team of Zyphar's Pharmaceutics comprises:

Mahendra Champalal Jain
Rajeshkumar Champalal Jain
Roshan Champalal Jain
Kapil Ganeshmal Sonigara

All directors were appointed on February 17, 2006. Specific roles and responsibilities within the company are not detailed in the available sources.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Zyphar's Pharmaceutics Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Zyphar's Pharmaceutics has a limited presence in highly regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates a focus on specific products without evidence of widespread regulatory approvals or market access in these regions. This suggests that the company may not have pursued or achieved significant market penetration in these territories.

2Emerging Markets

The company's export activities are primarily concentrated in Advanced Oncology and Biologics & Immunotherapy, therapeutic areas with significant demand in emerging markets. However, there is no specific information regarding Zyphar's Pharmaceutics' penetration in Africa, Latin America, or Southeast Asia. The absence of WHO prequalification or similar certifications indicates that the company may not have pursued these markets actively.

3Geographic Strategy

Zyphar's Pharmaceutics exhibits a concentrated geographic strategy, focusing on a limited number of products without diversification into multiple markets. This approach may mitigate risks associated with market entry but also limits potential revenue streams from a broader geographic footprint.

Zyphar's Pharmaceutics Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information indicating that Zyphar's Pharmaceutics has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. This suggests that the company may not have pursued or achieved FDA approvals for its products.

2WHO & EU GMP

The available data does not confirm that Zyphar's Pharmaceutics holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. This absence may limit the company's ability to access certain international markets that require such certifications.

3CDSCO & Indian Regulatory

Zyphar's Pharmaceutics is registered with the Central Drugs Standard Control Organisation (CDSCO) in India, as indicated by its Corporate Identification Number (CIN) U24231PN2006PTC022042. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available.

Zyphar's Pharmaceutics Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Zyphar's Pharmaceutics operates in the competitive pharmaceutical industry, focusing on oncology and biologics. While specific competitors are not identified in the available data, the company's concentrated product portfolio and limited market presence may position it as a niche player in these therapeutic areas.

2Key Differentiators

Zyphar's Pharmaceutics' focus on high-quality, cost-effective life-saving products in oncology and immunotherapy sets it apart. The company's commitment to delivering "Made in India" formulations matching global standards reflects its dedication to quality and international competitiveness.

3Strategic Position

Zyphar's Pharmaceutics appears to be strategically positioned as a manufacturer of specialized pharmaceutical formulations, particularly in oncology and biologics. The company's future outlook may involve expanding its product portfolio and pursuing regulatory approvals to access broader international markets.

Buyer Due Diligence Brief — Evaluating Zyphar's Pharmaceutics Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Zyphar's Pharmaceutics has demonstrated consistency in its export activities, with a total export value of $26K USD across 31 shipments. The company's focus on a limited number of products suggests a specialized approach to manufacturing and supply. However, the absence of certifications such as WHO prequalification or EU GMP may impact its reliability indicators in certain markets.

2Certifications to Verify

Importers should verify the following certifications before engaging with Zyphar's Pharmaceutics:

FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
WHO Prequalification: To assess eligibility for international procurement programs.
EU GMP Certificate: To ensure adherence to European manufacturing standards.

Verification can be conducted through the respective regulatory bodies' official websites or by direct communication with the company.

Frequently Asked Questions — Zyphar's Pharmaceutics Private Limited

How many pharmaceutical products does Zyphar's Pharmaceutics Private Limited export from India?

Zyphar's Pharmaceutics Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Procarbazine ($13.4K), Adalimumab ($9.4K), Lomustine ($3.3K). Total export value is $26.1K.

What is Zyphar's Pharmaceutics Private Limited's total pharmaceutical export value?

Zyphar's Pharmaceutics Private Limited's total pharmaceutical export value is $26.1K, based on 31 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Zyphar's Pharmaceutics Private Limited cover?

Zyphar's Pharmaceutics Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (64.1%, 2 products), Biologics & Immunotherapy (35.9%, 1 products).

Get Full Zyphar's Pharmaceutics Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.